NICE recommends first licenced treatment for AL amyloidosis
Having been available in Scotland and Northern Ireland since 2022, NICE’s positive opinion of the combination treatment means it is now accessible on the NHS.
List view / Grid view
Amyloidosis is a group of diseases in which abnormal protein, known as amyloid fibrils, builds up in tissue. Symptoms depend on the type and are often variable. They may include diarrhea, weight loss, feeling tired, enlargement of the tongue, bleeding, numbness, feeling faint with standing, swelling of the legs, or enlargement of the spleen.
There are about 30 different type of amyloidosis, each due to a specific protein misfolding. Some are genetic while others are acquired. They are grouped into localised and systemic forms. The four most common types of systemic disease are light chain (AL), inflammation (AA), dialysis (Aβ2M), and hereditary and old age (ATTR).
Diagnosis may be suspected when protein is found in the urine, organ enlargement is present, or problems are found with multiple peripheral nerves and it is unclear why. Diagnosis is confirmed by tissue biopsy. Due to the variable presentation, a diagnosis can often take some time to reach.
Treatment is geared towards decreasing the amount of the involved protein. This may sometimes be achieved by determining and treating the underlying cause. AL amyloidosis occurs in about 3–13 per million people per year and AA amyloidosis in about 2 per million people per year. The usual age of onset of these two types is 55 to 60 years old. Without treatment life expectancy is between half and four years. In the developed world about 1 per 1,000 people die from amyloidosis.
Having been available in Scotland and Northern Ireland since 2022, NICE’s positive opinion of the combination treatment means it is now accessible on the NHS.
A treatment for amyloidosis has been pulled from clinical trials after failing to reach endpoints.
3 August 2016 | By Prothena Corporation plc
Prothena Corporation plc has reported financial results for the second quarter and first six months of 2016. In addition, the Company provided an update on its R&D programs and 2016 financial guidance...
1 October 2015 | By Victoria White
Genzyme has elected to opt into the programme for development and potential future commercialisation of ALN-AT3 in territories outside of North America and Western Europe...
15 July 2015 | By Victoria White
Takeda has submitted an NDA to the US FDA for ixazomib for the treatment of patients with relapsed and/or refractory multiple myeloma...
21 May 2015 | By Victoria White
The FDA has granted Orphan Drug Designation to Alnylam’s revusiran for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis)...
12 May 2015 | By Victoria White
Takeda has announced that the first patient has been enrolled in the Phase 3 TOURMALINE-MM4 study of investigational oral ixazomib...
3 December 2014 | By Prothena
Prothena initiates NEOD001 global Phase 3 registrational trial based on positive results in ongoing phase 1/2 study of NEOD001 in Patients With AL Amyloidosis...
18 June 2012 | By Pfizer
Tafamidis is a novel, investigational medication for the treatment of TTR-FAP...
15 February 2012 | By Pfizer
A novel, investigational treatment for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)...